**Author details**

Laura Antolino1 \*, Paolo Aurello1 , Federico Todde2 , Silvia Amato1 , Niccolò Petrucciani3 , Andrea Kazemi Nava4 , Giuseppe Nigri1 , Stefano Valabrega1 , Giovanni Ramacciato1 and Francesco D'Angelo<sup>1</sup>

[7] Strobel O, Hank T, Hinz U, Bergmann F, Schneider L, Springfeld C, Jäger D, Schirmacher P, Hackert T, Büchler MW. Pancreatic cancer surgery: The new R-status counts. Annals

The Role of Neoadjuvant Therapy in Surgical Treatment of Pancreatic Cancer

http://dx.doi.org/10.5772/intechopen.76750

209

[8] Kim HS, Jang JY, Han Y, Lee KB, Joo I, Lee DH, Kim JR, Kim H, Kwon W, Kim SW. Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer. Annals of Surgical Treatment and

[9] Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. Journal of the American

[10] Ramacciato G, Nigri G, Petrucciani N, Pinna AD, Ravaioli M, Jovine E, Minni F, Grazi GL, Chirletti P, Tisone G, Napoli N, Boggi U. Pancreatectomy with mesenteric and portal vein resection for borderline resectable pancreatic cancer: Multicenter study of 406

[11] Hackert T, Ulrich A, Büchler MW. Can neoadjuvant therapy in pancreatic cancer increase the pool of patients eligible for pancreaticoduodenectomy? Advances in Surgery.

[12] Metha VK, Fisher G, Ford JA, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. Journal of Gastrointestinal Surgery. 2001;**5**:27-35

[13] Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer:

[14] Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, Pisters PW, Posner MC, Berlin JD, Ahmad SA. Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial

[15] Delpero JR, Boher JM, Sauvanet A, Le Treut YP, Sa-Cunha A, Mabrut JY, Chiche L, Turrini O, Bachellier P, Paye F. Pancreatic adenocarcinoma with venous involvement: Is upfront synchronous portal-superior mesenteric vein resection still justified? A survey of the Association Française de Chirurgie. Annals of Surgical Oncology. 2015;**22**(6):

[16] Matsumoto I, Murakami Y, Shinzeki M, Asari S, Goto T, Tani M, Motoi F, Uemura K, Sho M, Satoi S, Honda G, Yamaue H, Unno M, Akahori T, Kwon AH, Kurata M, Ajiki T, Fukumoto T, Ku Y. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-cen-

[17] Distler M, Pilarsky E, Kersting S, Grützmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of

Expert consensus statement. Annals of Surgical Oncology. 2009;**16**(7):1727-1733

of Surgery. 2017;**265**(3):565-573

Research. 2017;**93**(4):186-194

2017;**51**(1):1-10

1874-1883

College of Surgeons. 2008;**206**(5):833-846

patients. Annals of Surgical Oncology. 2016;**23**(6):2028-2037

design. Annals of Surgical Oncology. 2013;**20**(8):2787-2795

ter retrospective study. Pancreatology. 2015;**15**(6):674-680

\*Address all correspondence to: laura.antolino@uniroma1.it

1 General Surgery Unit, Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, Italy

2 Emergency Department, San Pietro Fatebenefratelli Hospital, Rome, Italy

3 Digestive Surgery and Liver Transplantation Unit, Henri Modor Hospital, Creteil, France

4 Liver Transplant Unit, St'Vincent University Hospital, Dublin, Ireland
